Allergan Biocell Textured Breast Implant Lawsuits To Be Selected For Bellwether Trial Discovery in August 2024

More than 1,200 lawsuits allege Allergan Biocell breast implants caused anaplastic large cell lymphoma (ALCL) and other injuries, due to a defective textured surface area design.

With similar questions of fact and law presented in hundreds of Allergan Biocell breast implant lawsuits filed throughout the federal court system, each involving allegations that the textured design caused users to develop a rare type of cancer known as breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the U.S. District Judge presiding over the cases has given the parties until the end of August to select a group of representative claims for a series of bellwether test trials.

Allergan’s Biocell breast implants were removed from the market in 2020, after health officials linked the textured design to nearly all reported cases of BIA-ALCL. Since then, the manufacturer has faced more than 1,200 lawsuits filed by women nationwide who developed the rare cancer in the tissue surrounding the textured breast implant.

Allergan also faces class action claims representing all women who received the recalled implants, which may result in the need for removal surgery or life-long medical monitoring due to the increased risk of cancer.

Allergan Biocell Breast Implant Problems

Concerns about the link between textured breast implants and ALCL began to emerge nearly 10 years ago, with hundreds of cases identified nationwide, including dozens of deaths. Since the cancer was nearly always diagnosed in women with breast implants, the medical community has come to refer to the cancer as “breast implant-associated” ALCL.

In June 2017, a study published in the medical journal Plastic and Reconstructive Surgery suggested that certain textured breast implants may be increasing the risk of ALCL, with results suggesting that women receiving the design may be anywhere from 10 to 14 times more likely to develop the cancer, when compared to those who received traditional, smooth breast implants.

Another study, published in October 2017, warned that many breast implant cancer cases worldwide have likely not been reported, and noted doctors and patients may not be aware of BIA-ALCL.

Learn More About

Breast Implant Lawsuits

Women may face a risk of Anaplastic Large Cell Lymphoma (ALCL) from certain breast implants.

Since December 2019, all Allergan Biocell textured breast implant lawsuits filed throughout the federal court system have been consolidated for pretrial proceedings before U.S. District Judge Brian R. Martinotti in the District of New Jersey, to reduce duplicative discovery into common issues, avoid conflicting pretrial schedules and serve the convenience of the parties, witnesses and the judicial system.

Early in the litigation, Judge Martinotti ordered the parties to select a pool of Initial Bellwether Discovery Cases by June 1, 2024, which would go through case-specific discovery and be prepared for a series of early test trials to help the parties determine how juries are likely to interpret testimony and evidence that was likely to be repeated throughout other Allergan Biocell textured breast implant lawsuits.

However, in a case management order (PDF) issued on May 16, Judge Martinotti extended that deadline to August 14, 2024.  In addition, the original instructions called for the completion of core discovery in those cases to be completed by October 31, 2024. That deadline has also been extended, to January 31, 2025.

On June 11, Judge Martinotti met with lawyers involved in the litigation for a status conference (PDF), at which time the Court reviewed progress of general discovery and waivers of venue that will be required for bellwether trials to go before juries in the District of New Jersey.

Following the jury trials, if the parties fail to negotiate Allergan Biocell breast implant settlements for women diagnosed with ALCL, it is expected that Judge Martinotti will consider remanding larger numbers of claims back to U.S. District Courts nationwide for individual trial dates.

1 Comments

  • LindaJune 24, 2024 at 3:03 am

    There is probably I’m pretty positive not a loan number of cases of Squamish cell carcinoma among women who had textured breast implants was a matter of fact it’s misdiagnosed it is ignored and I know because I am one of them and it’s very unfair unjust And I pray every night for this to change because this is not the way we should treat good people in this world. I feel like we’ve been used as gu[Show More]There is probably I’m pretty positive not a loan number of cases of Squamish cell carcinoma among women who had textured breast implants was a matter of fact it’s misdiagnosed it is ignored and I know because I am one of them and it’s very unfair unjust And I pray every night for this to change because this is not the way we should treat good people in this world. I feel like we’ve been used as guinea pigs and lied to over and over again.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery
Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery (Posted today)

A federal magistrate judge is forcing Uber to hand over potentially hundreds of thousands of incident files involving reports of passengers who suffered sexual misconduct or sexual assault at the hands of the rideshare service's drivers.

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted yesterday)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted 2 days ago)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.